nach oben

Erschienen in:

01.01.2012 | Original Paper

Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes

verfasst von: Luiz Felipe Domingues Passero, Cláudia Marques, Inês Vale-Gato, Carlos Eduardo Pereira Corbett, Márcia Dalastra Laurenti, Gabriela Santos-Gomes

Erschienen in: Archives of Dermatological Research | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Leishmania (Viannia) shawi causes cutaneous lesions in humans. Parasite antigens conferring significant protection against American tegumentar leishmaniosis (ATL) might be important for the development of effective vaccine. Therefore, this work evaluates the protective effect of antigenic fractions released by L. shawi. Antigens released by promastigotes to culture medium were concentrated and isolated by SDS-PAGE. The three main fractions LsPass1 (>75 kDa), LsPass2 (75–50 kDa) and LsPass3 (<50 kDa) were electro-eluted according with their molecular mass. Immunized BALB/c mice were challenged with L. shawi promastigotes and the course of infection monitored during 5 weeks. LsPass1-challenged mice showed no protection, however, a strong degree of protection associated to smaller lesions and high expression of IFN-γ and TNF-α by CD4⁺ T, CD8⁺ T and double negative CD4CD8 cells was achieved in LsPass3-challenged mice. Furthermore, LsPass2-challenged mice showed an intermediated degree of protection associated to high levels of IFN-γ, IL-4 and IL-10 mRNA. In spite of increased expression of IFN-γ and TNF-α, high amounts of IL-4 and IL-10 mRNA were also detected in LsPass3-challenged mice indicating a possible contribution of these cytokines for the persistence of a residual number of parasites that may be important in inducing long-lasting immunity. Therefore, LsPass3 seems to be an interesting alternative that should be considered in the development of an effective vaccine against ATL.

Bogdan C (2008) Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 10:1221–1234PubMedCrossRef

Brito ME, Andrade MS, Mendonça MG, Silva CJ, Almeida EL, Lima BS, Félix SM, Abath FG, da Graça GC, Porrozzi R, Ishikawa EA, Shaw JJ, Cupolillo E, Brandão-Filho SP (2009) Species diversity of Leishmania (Viannia) parasites circulating in an endemic area for cutaneous leishmaniasis located in the Atlantic rainforest region of northeastern Brazil. Trop Med Int Health 14:1278–1286PubMedCrossRef

Carneiro FP, De Magalhães AV, De Jesus Abreu Almeida Couto M, Bocca AL, Muniz-Junqueira MI, Ribeiro Sampaio RN (2009) Foxp3 expression in lesions of the different clinical forms of American tegumentary leishmaniasis. Parasite Immunol 31:646–651PubMedCrossRef

Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y (2009) Natural killer cells modulate overt autoimmunity to homeostasis in nonobese diabetic mice after anti-CD3 F(ab’)2 antibody treatment through secreting transforming growth factor-beta. Am J Pathol 175:1086–1094PubMedCrossRef

Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, Seder RA (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207:1421–1433PubMedCrossRef

Dunning O (2009) Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci Horiz 2:73–82CrossRef

Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath MG (2008) Transforming growth factor-beta suppresses the activation of CD8 + T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57:2684–2692PubMedCrossRef

Ivory C, Chadee K (2004) DNA vaccines: designing strategies against parasitic infections. Genet Vaccin Ther 2:17CrossRef

Kang JS, Liu C, Derynck R (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 19:385–394PubMedCrossRef

10.

Kaufmann SH, Hess J (1999) Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development. Immunol Lett 65:81–94PubMedCrossRef

11.

Kreutzer RD, Corredor A, Grimaldi G Jr, Grogl M, Rowton ED, Young DG, Morales A, McMahon-Pratt D, Guzman H, Tesh RB (1991) Characterization of Leishmania colombiensis sp. n (Kinetoplastida: Trypanosomatidae), a new parasite infecting humans, animals, and phlebotomine sand flies in Colombia and Panama. Am J Trop Med Hyg 44:662–675PubMed

12.

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685PubMedCrossRef

13.

Lainson R, Braga RR, De Souza AA, Pôvoa MM, Ishikawa EA, Silveira FT (1989) Leishmania (Viannia) shawi sp. n., a parasite of monkeys, sloths and procyonids in Amazonian, Brazil. Ann Parasitol Hum Comp 64:200–207PubMed

14.

Lainson R, Shaw JJ (1989) Leishmania (Viannia) naiffi sp. n., a parasite of the armadillo, Dasypus novemcinctus (L.) in Amazonian, Brazil. Ann Parasitol Hum Comp 64:3–9PubMed

15.

Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G (2005) Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23:2825–2840PubMedCrossRef

16.

Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G (2007) Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25:4223–4234PubMedCrossRef

17.

Liew FY, Li Y, Millott S (1990) Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145:4306–4310PubMed

18.

Nagill R, Mahajan R, Sharma M, Kaur S (2009) Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 58:359–366PubMedCrossRef

19.

Naundorf S, Schröder M, Höflich C, Suman N, Volk HD, Grütz G (2009) IL-10 interferes directly with TCR-induced IFN-gamma but not IL-17 production in memory T cells. Eur J Immunol 39:1066–1077PubMedCrossRef

20.

Novoa R, Bacellar O, Nascimento M, Cardoso TM, Ramasawmy R, Oliveira WN, Schriefer A, Carvalho EM (2011) IL-17 and regulatory cytokines (IL-10 and IL-27) in L. braziliensis infection. Parasite Immunol 33:132–136PubMedCrossRef

21.

Okwor I, Uzonna J (2008) Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 41:123–136PubMedCrossRef

22.

O’Daly JA, Lezama R, Rodriguez PJ, Silva E, Indriago NR, Peña G, Colorado I, Gleason J, Rodríguez B, Acuña L, Ovalles T (2009) Antigens from Leishmania amastigotes induced clinical remission of psoriasis. Arch Dermatol Res 301:1–13PubMedCrossRef

23.

O’Daly JA, Lezama R, Gleason J (2009) Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis. Arch Dermatol Res 301:411–427PubMedCrossRef

24.

O’Daly JA, Rodriguez B, Ovalles T, Pelaez C (2010) Lymphocyte subsets in peripheral blood of patients with psoriasis before and after treatment with Leishmania antigens. Arch Dermatol Res 302:95–104PubMedCrossRef

25.

O’Daly JA, Gleason JP, Peña G, Colorado I (2010) Purified proteins from Leishmania amastigotes-induced delayed type hypersensitivity reactions and remission of collagen-induced arthritis in animal models. Arch Dermatol Res 302:567–581PubMedCrossRef

26.

O’Daly JA, Gleason J, Lezama R, Rodriguez PJ, Silva E, Indriago NR (2011) Antigens from Leishmania amastigotes inducing clinical remission of psoriatic arthritis. Arch Dermatol Res 303:399–415PubMedCrossRef

27.

Passero LFD, Sacomori JV, Tomokane TY, Corbett CE, da Silveira FT, Laurenti MD (2009) Ex vivo and in vivo biological behavior of Leishmania (Viannia) shawi. Parasitol Res 105:1741–1747PubMedCrossRef

28.

Passero LFD, Marques C, Vale-Gato I, Corbett CEP, Laurenti MD, Santos-Gomes G (2010) Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi. Parasitol Int 59:159–165PubMedCrossRef

29.

Passero LF, Da Costa Bordon ML, De Carvalho AK, Martins LM, Corbett CE, Laurenti MD (2010) Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms. APMIS 118:973–981PubMedCrossRef

30.

Rodrigues OR, Moura RA, Gomes-Pereira S, Santos-Gomes GM (2006) H-2 complex influences cytokine gene expression in Leishmania infantum-infected macrophages. Cell Immunol 243:118–126PubMedCrossRef

31.

Rodrigues OR, Marques C, Soares-Clemente M, Ferronha MH, Santos-Gomes GM (2009) Identification of regulatory T cells during experimental Leishmania infantum infection. Immunobiology 214:101–111PubMedCrossRef

32.

Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J (2007) Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25:7962–7971PubMedCrossRef

33.

Rosa R, Rodrigues OR, Marques C, Santos-Gomes GM (2005) Leishmania infantum soluble proteins released by the parasite exert differential effects on host immune response. Exp Parasitol 109:106–114PubMedCrossRef

34.

Rosa R, Marques C, Rodrigues OR, Santos-Gomes GM (2007) Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response. Vaccine 25:4525–4532PubMedCrossRef

35.

Santarém N, Silvestre R, Tavares J, Silva M, Cabral S, Maciel J, Cordeiro-da-Silva A (2007) Immune response regulation by Leishmania secreted and nonsecreted antigens. J Biomed Biotechnol 6:85154

36.

Shanmugasundaram R, Selvaraj RK (2010) In vitro human TGF-beta treatment converts CD4(+)CD25(−) T cells into induced T regulatory like cells. Vet Immunol Immunopathol 137:161–165PubMedCrossRef

37.

Shaw JJ, Ishikawa EA, Lainson R, Braga RR, Silveira FT (1991) Cutaneous leishmaniasis of man due to Leishmania (Viannia) shawi Lainson, de Souza, Póvoa, Ishikawa & Silveira, in Pará State, Brazil. Ann Parasitol Hum Comp 66:243–246PubMed

38.

Silveira FT, Ishikawa EA, De Souza AA, Lainson R (2002) An outbreak of cutaneous leishmaniasis among soldiers in Belém, Pará State, Brazil, caused by Leishmania (Viannia) lindenbergi n. sp. A new leishmanial parasite of man in the Amazon region. Parasite 9:43–50PubMed

39.

Silveira FT, Lainson R, Corbett CE (2004) Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99:239–241PubMedCrossRef

40.

Souza-Lemos C, de-Campos SN, Teva A, Côrte-Real S, Fonseca EC, Porrozzi R, Grimaldi G Jr (2008) Dynamics of immune granuloma formation in a Leishmania braziliensis-induced self-limiting cutaneous infection in the primate Macaca mulatta. J Pathol 216:375–386PubMedCrossRef

41.

Taylor AW (2009) Review of the activation of TGF-beta in immunity. J Leukoc Biol 85:29–33PubMedCrossRef

42.

Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS, Martin SK, Titus RG (2004) Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 72:5654–5661PubMedCrossRef

43.

Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 1247:1465–1468CrossRef

Titel: Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes
verfasst von: Luiz Felipe Domingues Passero
Cláudia Marques
Inês Vale-Gato
Carlos Eduardo Pereira Corbett
Márcia Dalastra Laurenti
Gabriela Santos-Gomes
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 1/2012
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-011-1171-7

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Dermatologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Erratum to: Duration of wound fluid secretion from chronic venous leg ulcers is critical for interleukin-1α, interleukin-1β, interleukin-8 levels and fibroblast activation

Expression of bleomycin hydrolase in keratinization disorders

In search of oral psoriasis

Long-term ultraviolet A irradiation of the eye induces photoaging of the skin in mice

The expressions of ABCC4 and ABCG2 xenobiotic transporters in human keratinocytes are proliferation-related

Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Dermatologie